{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T14:29:49Z","timestamp":1776522589162,"version":"3.51.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Persisting coma is a common complication in (neuro)intensive care in neurological disease such as acute ischemic stroke, intracerebral hemorrhage or subarachnoid hemorrhage. Amantadine acts as a nicotinic receptor antagonist, dopamine receptor agonist and non-competitive N-Methyl-D-aspartate receptor antagonist. Amantadine is a long-known drug, originally approved for treatment of influenza A and Parkinson`s Disease. It has been proven effective in improving vigilance after traumatic brain injury. The underlying mechanisms remain largely unknown, albeit anti-glutamatergic and dopaminergic effects might be most relevant. With limited evidence of amantadine efficacy in non-traumatic pathologies, the aim of our study is to assess the effects of amantadine for neuroenhancement in non-traumatic neurointensive patients with persisting coma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An investigator-initiated, monocenter, phase IIb proof of concept open-label pilot study will be carried out. Based on the Simon design, 43 adult (neuro)intensive care patients who meet the clinical criteria of persisting coma not otherwise explained and &lt;\u20098 points on the Glasgow Coma Scale (GCS) will be recruited. Amantadine will be administered intravenously for five days at a dosage of 100\u00a0mg bid. The primary endpoint is an improvement of at least 3 points on the GCS. If participants present as non-responders (increase\u2009&lt;\u20093 points or decrease on the GCS) within the first 48\u00a0h, the dosage will be doubled from day three to five. Secondary objectives aim to demonstrate that amantadine improves vigilance via alternative scales. Furthermore, the incidence of adverse events will be investigated and electroencephalography (EEG) will be recorded at baseline and end of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The results of our study will help to systematically assess the clinical utility of amantadine for treatment of persisting coma in non-traumatic brain injury. We expect that, in the face of only moderate treatment risk, a relevant number of patients will benefit from amantadine medication by improved vigilance (GCS increase of at least 3 points) finally leading to a better rehabilitation potential and improved functional neurological outcome. Further, the EEG data will allow evaluation of brain network states in relation to vigilance and potentially outcome prediction in this study cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>NCT05479032.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-023-03345-w","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:01:56Z","timestamp":1692702116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES)"],"prefix":"10.1186","volume":"23","author":[{"given":"Anna","family":"Hofmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinna","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constanze","family":"Single","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Adeyemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasileios","family":"Siokas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim W.","family":"Rattay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene A.","family":"H\u00e4berle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reimer","family":"Riessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Haug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"B\u00f6sel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manola","family":"Zago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Martus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annerose","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Feil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"issue":"5","key":"3345_CR1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/ene.14151","volume":"27","author":"D Kondziella","year":"2020","unstructured":"Kondziella D, Bender A, Diserens K, van Erp W, Estraneo A, Formisano R, et al. European Academy of Neurology guideline on the diagnosis of coma and other disorders of consciousness. Eur J Neurol. 2020;27(5):741\u201356.","journal-title":"Eur J Neurol"},{"key":"3345_CR2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1741-7015-8-68","volume":"8","author":"S Laureys","year":"2010","unstructured":"Laureys S, Celesia GG, Cohadon F, Lavrijsen J, Le\u00f3n-Carri\u00f3n J, Sannita WG, et al. Unresponsive wakefulness syndrome: a new name for the vegetative state or apallic syndrome. BMC Med. 2010;8:68.","journal-title":"BMC Med"},{"issue":"3","key":"3345_CR3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1212\/WNL.58.3.349","volume":"58","author":"JT Giacino","year":"2002","unstructured":"Giacino JT, Ashwal S, Childs N, Cranford R, Jennett B, Katz DI, et al. The minimally conscious state: definition and diagnostic criteria. Neurology. 2002;58(3):349\u201353.","journal-title":"Neurology"},{"issue":"18","key":"3345_CR4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/WNL.0000000000011715","volume":"96","author":"D Kondziella","year":"2021","unstructured":"Kondziella D, Frontera JA, Pearls. Oy-sters: eyes-open coma. Neurology. 2021;96(18):864\u20137.","journal-title":"Neurology"},{"issue":"1","key":"3345_CR5","doi-asserted-by":"crossref","first-page":"13170","DOI":"10.1038\/s41598-020-70172-1","volume":"10","author":"J Li","year":"2020","unstructured":"Li J, Zhang P, Wu S, Yuan R, Liu J, Tao W, et al. Impaired consciousness at stroke onset in large hemisphere infarction: incidence, risk factors and outcome. Sci Rep. 2020;10(1):13170.","journal-title":"Sci Rep"},{"issue":"8","key":"3345_CR6","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1161\/STROKEAHA.118.023710","volume":"50","author":"SH Jang","year":"2019","unstructured":"Jang SH, Chang CH, Jung YJ, Kim JH, Kwon YH. Relationship between impaired consciousness and Injury of Ascending Reticular activating system in patients with Intracerebral Hemorrhage. Stroke. 2019;50(8):2234\u20137.","journal-title":"Stroke"},{"issue":"4","key":"3345_CR7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3174\/ajnr.A4203","volume":"36","author":"SH Jang","year":"2015","unstructured":"Jang SH, Kim HS. Aneurysmal Subarachnoid Hemorrhage causes Injury of the Ascending Reticular Activating System: relation to consciousness. AJNR Am J Neuroradiol. 2015;36(4):667\u201371.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"3345_CR8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMra052732","volume":"354","author":"JI Suarez","year":"2006","unstructured":"Suarez JI, Tarr RW, Selman WR. Aneurysmal Subarachnoid Hemorrhage. N Engl J Med. 2006;354(4):387\u201396.","journal-title":"N Engl J Med"},{"issue":"1","key":"3345_CR9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(09)70266-2","volume":"9","author":"S Kumar","year":"2010","unstructured":"Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol. 2010;9(1):105\u201318.","journal-title":"Lancet Neurol"},{"issue":"6","key":"3345_CR10","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1161\/STR.0000000000000015","volume":"45","author":"RG Holloway","year":"2014","unstructured":"Holloway RG, Arnold RM, Creutzfeldt CJ, Lewis EF, Lutz BJ, McCann RM, et al. Palliative and end-of-life care in stroke: a statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014;45(6):1887\u2013916.","journal-title":"Stroke"},{"issue":"1","key":"3345_CR11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ana.24423","volume":"78","author":"ES Lutkenhoff","year":"2015","unstructured":"Lutkenhoff ES, Chiang J, Tshibanda L, Kamau E, Kirsch M, Pickard JD, et al. Thalamic and extrathalamic mechanisms of consciousness after severe brain injury: Brain Injury and consciousness. Ann Neurol. 2015;78(1):68\u201376.","journal-title":"Ann Neurol"},{"issue":"1","key":"3345_CR12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1749-6632.2009.04471.x","volume":"1157","author":"GB Young","year":"2009","unstructured":"Young GB. Coma. Annals of the New York. Acad Sci. 2009;1157(1):32\u201347.","journal-title":"Acad Sci"},{"key":"3345_CR13","doi-asserted-by":"crossref","unstructured":"Claren\u00e7on F, Bardinet \u00c9, Martinerie J, Pelbarg V, Menjot de Champfleur N, Gupta R et al. Lesions in deep gray nuclei after severe traumatic brain injury predict neurologic outcome. Mohapatra S, editor. PLoS ONE. 2017;12(11):e0186641.","DOI":"10.1371\/journal.pone.0186641"},{"key":"3345_CR14","doi-asserted-by":"crossref","unstructured":"Brown EN, Lydic R, Schiff ND. General Anesthesia, Sleep, and Coma. Schwartz RS, editor. N Engl J Med. 2010;363(27):2638\u201350.","DOI":"10.1056\/NEJMra0808281"},{"issue":"S1","key":"3345_CR15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12028-021-01227-y","volume":"35","author":"BL Edlow","year":"2021","unstructured":"Edlow BL, Sanz LRD, Polizzotto L, Pouratian N, Rolston JD, Snider SB, et al. Therapies to restore consciousness in patients with severe brain injuries: a gap analysis and future directions. Neurocrit Care. 2021;35(S1):68\u201385.","journal-title":"Neurocrit Care"},{"issue":"2","key":"3345_CR16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00702-021-02306-2","volume":"128","author":"W Danysz","year":"2021","unstructured":"Danysz W, Dekundy A, Scheschonka A, Riederer P. Amantadine: reappraisal of the timeless diamond\u2014target updates and novel therapeutic potentials. J Neural Transm. 2021;128(2):127\u201369.","journal-title":"J Neural Transm"},{"issue":"1","key":"3345_CR17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-2999(71)90053-7","volume":"16","author":"LO Farnebo","year":"1971","unstructured":"Farnebo LO, Fuxe K, Goldstein M, Hamberger B, Ungerstedt U. Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson\u2019s disease. Eur J Pharmacol. 1971;16(1):27\u201338.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3345_CR18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s100720170067","volume":"22","author":"MA Volont\u00e9","year":"2001","unstructured":"Volont\u00e9 MA, Moresco RM, Gobbo C, Messa C, Carpinelli A, Rizzo G, et al. A PET study with [11-C]raclopride in Parkinson\u2019s disease: preliminary results on the effect of amantadine on the dopaminergic system. Neurol Sci. 2001;22(1):107\u20138.","journal-title":"Neurol Sci"},{"issue":"1\u20132","key":"3345_CR19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0006-8993(94)90821-4","volume":"662","author":"K Mizoguchi","year":"1994","unstructured":"Mizoguchi K, Yokoo H, Yoshida M, Tanaka T, Tanaka M. Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-d-aspartate antagonism. Brain Res. 1994;662(1\u20132):255\u20138.","journal-title":"Brain Res"},{"issue":"10","key":"3345_CR20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1212\/WNL.0000000000005926","volume":"91","author":"JT Giacino","year":"2018","unstructured":"Giacino JT, Katz DI, Schiff ND, Whyte J, Ashman EJ, Ashwal S, et al. Practice guideline update recommendations summary: Disorders of consciousness: report of the Guideline Development, Dissemination, and implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research. Neurology. 2018;91(10):450\u201360.","journal-title":"Neurology"},{"issue":"9","key":"3345_CR21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1102609","volume":"366","author":"JT Giacino","year":"2012","unstructured":"Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. Placebo-controlled trial of amantadine for severe traumatic brain Injury. N Engl J Med. 2012;366(9):819\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"3345_CR22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12028-020-00977-5","volume":"33","author":"DJ Gagnon","year":"2020","unstructured":"Gagnon DJ, Leclerc AM, Riker RR, Brown CS, May T, Nocella K, et al. Amantadine and Modafinil as Neurostimulants during Post-stroke Care: a systematic review. Neurocrit Care. 2020;33(1):283\u201397.","journal-title":"Neurocrit Care"},{"key":"3345_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/964578","volume":"2014","author":"AA Herrold","year":"2014","unstructured":"Herrold AA, Pape TLB, Guernon A, Mallinson T, Collins E, Jordan N. Prescribing multiple neurostimulants during Rehabilitation for severe Brain Injury. Sci World J. 2014;2014:1\u20137.","journal-title":"Sci World J"},{"key":"3345_CR24","first-page":"383","volume":"19","author":"I Jibiki","year":"1993","unstructured":"Jibiki I, Morikawa K, Yamaguchi N. Beneficial effect of amantadine on symptoms of dementia in patients with cerebral infarctions. Acta Ther. 1993;19:383\u20137.","journal-title":"Acta Ther"},{"key":"3345_CR25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neulet.2018.01.023","volume":"668","author":"E Landucci","year":"2018","unstructured":"Landucci E, Filippi L, Gerace E, Catarzi S, Guerrini R, Pellegrini-Giampietro DE. Neuroprotective effects of topiramate and memantine in combination with hypothermia in hypoxic-ischemic brain injury in vitro and in vivo. Neurosci Lett. 2018;668:103\u20137.","journal-title":"Neurosci Lett"},{"key":"3345_CR26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fnsyn.2018.00018","volume":"10","author":"A Gower","year":"2018","unstructured":"Gower A, Tiberi M. The intersection of central dopamine system and stroke: potential avenues aiming at Enhancement of Motor Recovery. Front Synaptic Neurosci. 2018;10:18.","journal-title":"Front Synaptic Neurosci"},{"issue":"6","key":"3345_CR27","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1161\/STR.0000000000000098","volume":"47","author":"CJ Winstein","year":"2016","unstructured":"Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, et al. Guidelines for adult Stroke Rehabilitation and Recovery: a Guideline for Healthcare Professionals from the American Heart Association\/American Stroke Association. Stroke. 2016;47(6):e98\u2013169.","journal-title":"Stroke"},{"issue":"8","key":"3345_CR28","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1080\/02699052.2018.1476733","volume":"32","author":"H Ghalaenovi","year":"2018","unstructured":"Ghalaenovi H, Fattahi A, Koohpayehzadeh J, Khodadost M, Fatahi N, Taheri M, et al. The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial. Brain Injury. 2018;32(8):1050\u20135.","journal-title":"Brain Injury"},{"issue":"1","key":"3345_CR29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12028-020-00986-4","volume":"34","author":"AM Leclerc","year":"2021","unstructured":"Leclerc AM, Riker RR, Brown CS, May T, Nocella K, Cote J, et al. Amantadine and Modafinil as Neurostimulants following Acute Stroke: a retrospective study of Intensive Care Unit Patients. Neurocrit Care. 2021;34(1):102\u201311.","journal-title":"Neurocrit Care"},{"issue":"4","key":"3345_CR30","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ana.20611","volume":"58","author":"EFM Wijdicks","year":"2005","unstructured":"Wijdicks EFM, Bamlet WR, Maramattom BV, Manno EM, McClelland RL. Validation of a new coma scale: the FOUR score. Ann Neurol. 2005;58(4):585\u201393.","journal-title":"Ann Neurol"},{"issue":"10","key":"3345_CR31","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1164\/rccm.2107138","volume":"166","author":"CN Sessler","year":"2002","unstructured":"Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O\u2019Neal PV, Keane KA, et al. The Richmond agitation-sedation scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166(10):1338\u201344.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3345_CR32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/jnnp.44.4.285","volume":"44","author":"B Jennett","year":"1981","unstructured":"Jennett B, Snoek J, Bond MR, Brooks N. Disability after severe head injury: observations on the use of the Glasgow Outcome Scale. J Neurol Neurosurg Psychiatry. 1981;44(4):285\u201393.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"3345_CR33","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1089\/neu.2020.7527","volume":"38","author":"L Wilson","year":"2021","unstructured":"Wilson L, Boase K, Nelson LD, Temkin NR, Giacino JT, Markowitz AJ, et al. A manual for the Glasgow Outcome Scale-Extended interview. J Neurotrauma. 2021;38(17):2435\u201346.","journal-title":"J Neurotrauma"},{"issue":"12","key":"3345_CR34","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.apmr.2004.02.033","volume":"85","author":"JT Giacino","year":"2004","unstructured":"Giacino JT, Kalmar K, Whyte J, The, JFK Coma Recovery Scale-Revised. Measurement characteristics and diagnostic utility11No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated. Arch Phys Med Rehabil. 2004;85(12):2020\u20139.","journal-title":"Arch Phys Med Rehabil"},{"issue":"5","key":"3345_CR35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s001340100909","volume":"27","author":"N Bergeron","year":"2001","unstructured":"Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med. 2001;27(5):859\u201364.","journal-title":"Intensive Care Med"},{"issue":"9","key":"3345_CR36","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/01.STR.0000027437.22450.BD","volume":"33","author":"JTL Wilson","year":"2002","unstructured":"Wilson JTL, Hareendran A, Grant M, Baird T, Schulz UGR, Muir KW, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke. 2002;33(9):2243\u20136.","journal-title":"Stroke"},{"issue":"1","key":"3345_CR37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jphys.2013.12.012","volume":"60","author":"LK Kwah","year":"2014","unstructured":"Kwah LK, Diong J. National Institutes of Health Stroke Scale (NIHSS). J Physiother. 2014;60(1):61.","journal-title":"J Physiother"},{"issue":"4","key":"3345_CR38","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00c3\u00a9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief Screening Tool for mild cognitive impairment: MOCA: a BRIEF SCREENING TOOL FOR MCI. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"3345_CR39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12883-015-0469-z","volume":"15","author":"A Hankemeier","year":"2015","unstructured":"Hankemeier A, Rollnik JD. The early functional abilities (EFA) scale to assess neurological and neurosurgical early rehabilitation patients. BMC Neurol. 2015;15(1):207.","journal-title":"BMC Neurol"},{"key":"3345_CR40","doi-asserted-by":"crossref","first-page":"654541","DOI":"10.3389\/fnsys.2022.654541","volume":"16","author":"A Duszyk-Bogorodzka","year":"2022","unstructured":"Duszyk-Bogorodzka A, Zieleniewska M, Jankowiak-Siuda K. Brain activity characteristics of patients with Disorders of consciousness in the EEG resting state paradigm: a review. Front Syst Neurosci. 2022;16:654541.","journal-title":"Front Syst Neurosci"},{"issue":"11","key":"3345_CR41","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1007\/s00415-020-10095-z","volume":"268","author":"Y Bai","year":"2021","unstructured":"Bai Y, Lin Y, Ziemann U. Managing disorders of consciousness: the role of electroencephalography. J Neurol. 2021;268(11):4033\u201365.","journal-title":"J Neurol"},{"key":"3345_CR42","unstructured":"Fachinforation. Amantadin-ratiopharm 200\u00a0mg Infusionsl\u00f6sung. 2018."},{"issue":"4","key":"3345_CR43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/02699052.2012.750758","volume":"27","author":"M Leonardi","year":"2013","unstructured":"Leonardi M, Sattin D, Raggi A. An italian population study on 600 persons in vegetative state and minimally conscious state. Brain Injury. 2013;27(4):473\u201384.","journal-title":"Brain Injury"},{"issue":"03","key":"3345_CR44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1055\/s-0042-1755271","volume":"42","author":"ME Barra","year":"2022","unstructured":"Barra ME, Edlow BL, Brophy GM. Pharmacologic therapies to promote recovery of consciousness. Semin Neurol. 2022;42(03):335\u201347.","journal-title":"Semin Neurol"},{"key":"3345_CR45","doi-asserted-by":"crossref","first-page":"105815","DOI":"10.1016\/j.clineuro.2020.105815","volume":"194","author":"A Loggini","year":"2020","unstructured":"Loggini A, Tangonan R, El Ammar F, Mansour A, Goldenberg FD, Kramer CL, et al. The role of amantadine in cognitive recovery early after traumatic brain injury: a systematic review. Clin Neurol Neurosurg. 2020;194:105815.","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"3345_CR46","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/jnnp-2021-327408","volume":"93","author":"L R\u00fchl","year":"2022","unstructured":"R\u00fchl L, Kuramatsu JB, Sembill JA, Kallm\u00fcnzer B, Madzar D, Gerner ST, et al. Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury. J Neurol Neurosurg Psychiatry. 2022;93(6):582\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"3345_CR47","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00001199-200208000-00004","volume":"17","author":"JM Meythaler","year":"2002","unstructured":"Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to Improve Neurorecovery in Traumatic Brain Injury\u2013Associated diffuse Axonal Injury: a pilot double-blind Randomized Trial. J Head Trauma Rehabilitation. 2002;17(4):300\u201313.","journal-title":"J Head Trauma Rehabilitation"},{"key":"3345_CR48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jns.2018.04.022","volume":"390","author":"ME Reznik","year":"2018","unstructured":"Reznik ME, Yaghi S, Jayaraman MV, McTaggart RA, Hemendinger M, Mac Grory BC, et al. Level of consciousness at discharge and associations with outcome after ischemic stroke. J Neurol Sci. 2018;390:102\u20137.","journal-title":"J Neurol Sci"},{"issue":"4","key":"3345_CR49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000232927","volume":"62","author":"A Brioschi","year":"2009","unstructured":"Brioschi A, Gramigna S, Werth E, Staub F, Ruffieux C, Bassetti C, et al. Effect of Modafinil on subjective fatigue in multiple sclerosis and stroke patients. Eur Neurol. 2009;62(4):243\u20139.","journal-title":"Eur Neurol"},{"issue":"5","key":"3345_CR50","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.12.011","volume":"23","author":"T Askim","year":"2014","unstructured":"Askim T, Bernhardt J, Salvesen \u00d8, Indredavik B. Physical activity early after Stroke and its association to functional outcome 3 months later. J Stroke Cerebrovasc Dis. 2014;23(5):e305\u201312.","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03345-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03345-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03345-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T02:14:07Z","timestamp":1700273647000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03345-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3345"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03345-w","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"3 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katharina Feil and Annerose Mengel are funded by AKF (\u201cAngewandte Klinische Forschung\u201d = applied clinical research) grant of the medical faculty of T\u00fcbingen University (No. 496-0-0). Katharina Feil received speaker honoraria from Pfizer, study funding for Lexi Study (Boehringer Ingelheim). The remaining authors have no conflicts of interest to declare. AH: None. CB: None. CS: None. KA: None. PS: None. VS: None. TWR: None. HAH: None. RR: None. BB: None. IH: None. RB: None. MZ: None. PM: None. UZ: None. AM: None. KF: Received speaker honoraria from Pfizer, study funding for Lexi Study (Boehringer Ingelheim)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol has been approved by the local Clinical Research Ethics Committee of the University Hospital Tuebingen and has been registered at ClinicalTrials.gov with the number NCT05479032. The study will follow the ethical principles for medical research involving human subjects of the Declaration of Helsinki, adopted by the 18th General Assembly of the World Medical Association (World Medical Association, 1964). All subjects and\/or their proxies will provide informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"308"}}